Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPAAARI
2024-517004-11-00Phase 3Authorised
- Sponsor
- CHU de Poitiers
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in chronic pulmonary aspergillosis (CPA) comparing Itraconazole monotherapy with Itraconazole + nebulised AmBisome (2 arms). Primary endpoint: Therapeutic efficacy at 6 months. Planned start Oct 2024; status: authorised.
02
Drugs
itraconazoleamphotericin b
03
Conditions
chronic pulmonary aspergillosis (CPA)
Beyond the preview
Go deeper on 2024-517004-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517004-11-00.